DNA testing for CDC73 mutations has been quite beneficial in clinical practice, based on expert opinion and published reports, although it must be acknowledged that high‐quality evidence of improved outcomes; eg, from randomized studies, are lacking—in large part due to the rarity of HPT‐JT and parathyroid carcinoma. Here, CDC73 is linked to parathyroid gland carcinoma.